[go: up one dir, main page]

AU2003272591A1 - Glioma treatments - Google Patents

Glioma treatments

Info

Publication number
AU2003272591A1
AU2003272591A1 AU2003272591A AU2003272591A AU2003272591A1 AU 2003272591 A1 AU2003272591 A1 AU 2003272591A1 AU 2003272591 A AU2003272591 A AU 2003272591A AU 2003272591 A AU2003272591 A AU 2003272591A AU 2003272591 A1 AU2003272591 A1 AU 2003272591A1
Authority
AU
Australia
Prior art keywords
glioma
treatments
glioma treatments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003272591A
Other versions
AU2003272591A8 (en
Inventor
Julian T. Hoff
Ya Hua
Richard F. Keep
Guohua Xi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Publication of AU2003272591A8 publication Critical patent/AU2003272591A8/en
Publication of AU2003272591A1 publication Critical patent/AU2003272591A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003272591A 2002-09-23 2003-09-23 Glioma treatments Abandoned AU2003272591A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41290902P 2002-09-23 2002-09-23
US60/412,909 2002-09-23
PCT/US2003/029582 WO2004026252A2 (en) 2002-09-23 2003-09-23 Glioma treatments

Publications (2)

Publication Number Publication Date
AU2003272591A8 AU2003272591A8 (en) 2004-04-08
AU2003272591A1 true AU2003272591A1 (en) 2004-04-08

Family

ID=32030940

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003272591A Abandoned AU2003272591A1 (en) 2002-09-23 2003-09-23 Glioma treatments

Country Status (2)

Country Link
AU (1) AU2003272591A1 (en)
WO (1) WO2004026252A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543843A (en) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New indications for direct thrombin inhibitors
JP5577094B2 (en) * 2006-08-31 2014-08-20 エミスフェアー・テクノロジーズ・インク Compounds and compositions for delivering active agents
US7687516B2 (en) 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
WO2008039473A2 (en) 2006-09-27 2008-04-03 Scidose Llc Alcohol free formulation of argatroban
WO2008045410A2 (en) * 2006-10-11 2008-04-17 Scidose Llc Alcohol free formulation of argatroban
WO2014152715A1 (en) * 2013-03-15 2014-09-25 University Of Rochester Use of inhibitors of binding between a par-1 receptor and its ligands for the treatment of glioma
US11821043B2 (en) 2017-08-17 2023-11-21 Nantomics Llc Dynamic changes in circulating free RNA of neural tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963655A (en) * 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
AU659432B2 (en) * 1991-03-08 1995-05-18 Novartis Ag A method for the inhibition or prevention of tumor cell metastasis with hirudin
EP0944619B1 (en) * 1996-11-27 2006-10-11 Bristol-Myers Squibb Pharma Company Novel integrin receptor antagonists

Also Published As

Publication number Publication date
AU2003272591A8 (en) 2004-04-08
WO2004026252A2 (en) 2004-04-01
WO2004026252A3 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
AU2003274037A1 (en) 1-phenylpyrrolidine-2-one-3-carboxamides
AU2003241030A1 (en) Opteolectronic devices
AU2002952554A0 (en) Monitower
AU2003247005A1 (en) Therapy combination
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
AU2003290818A1 (en) Topoisomerase-targeting agents
AU2003268504A1 (en) Whale-safe rope
GB0221574D0 (en) Treatments
AU2003272591A1 (en) Glioma treatments
AU2003212773A1 (en) Boosterantenna
AU2002318053A1 (en) Suplier
AU2003212130A1 (en) Can
AU2002100471A4 (en) Timber treatment
AUPS283402A0 (en) Combination therapy
AU2002100602A4 (en) Bonsystem
AU2002100280A4 (en) Proshoe
AU2002100510A4 (en) Bottlenecker
AU2002100655A4 (en) Armamulch
AU2002100957A4 (en) Sluggit
AU2002100739A4 (en) Neuramax
AU2002100160A4 (en) Oxidirator
AU2002100541A4 (en) Backmate
AU2002100498A4 (en) Linline
AU2002100468A4 (en) Flexi-edger
AU2002100747A4 (en) Powersell

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase